secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097603
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics posts corporate investor presentation; no new data in filing excerpt
--------------------------------------------------------------------------------

- Slide deck titled 'Unlocking the Potential of Immuno-Oncology Therapies' dated March 9, 2026.
- Presentation made available on company's website; no specific pipeline or financial details provided in this extract.
- Regulatory filing solely covers Reg FD disclosure of routine investor materials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526097603/0001193125-26-097603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526097603/xlo-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer